View More

CUREXO received approval from Japan's PMDA

On March 17, CUREXO received approval from Japan's Pharmaceuticals and Medical Devices Agency(PMDA) for the manufacturing and sales of CUVIS-joint, a robotic system for artificial joint surgery. As a result, We will begin sales of the CUVIS-joint in Japan through KYOCERA Global, who holds the exclusive distribution rights in the country.

View More

CUREXO INC.'S ROBOTIC GAIT TRAINING SYSTEM, MORNING WALK S200, INSTALLED IN FIRST US INPATIENT REHABILITATION FACILITY

In continuing its strategic partnership with Curexo, Inc. announced last year, Harmonic Bionics has completed the first installation of Curexo's Morning Walk S200 at an inpatient rehabilitation facility in the US.The Morning Walk S200 is an FDA-registered robotic gait rehabilitation system with a virtual reality component that uses a saddle for weight support and individual foot plates to facilitate more natural walking patterns. Last year, the device was installed at the first outpatient facility in the country. St. David's Rehabilitation Hospital, which is located at St. David's Medical Center in Austin, TX, is the first inpatient rehabilitation facility in the US to offer gait training with Morning Walk for patients. St. David's Medical Center was recently named as the top performing Large Community Hospital in the U.S. on the annual Fortune/Merative 100 Top Hospitals® list. The hospital's 64-bed rehabilitation facility provides comprehensive inpatient and outpatient care for patients with neurological conditions, including stroke and orthopedic illnesses or injuries."This is a major milestone for the Morning Walk device as we continue to validate the technology in different settings allowing more patients to experience Morning Walk in America," said Harmonic Bionics CEO Christopher Prentice. "We are excited to see the device at such a renowned institution right here in Austin and look forward to working with the St. David's team."For more information on Morning Walk S200, please email info@morningwalk.us.About Harmonic Bionics, Inc.Harmonic Bionics aims to empower patients and their care providers by designing intelligent technology that facilitates data-driven treatment for neurological and musculoskeletal movement impairments. Our flagship product, Harmony SHR, is a bilateral upper extremity exoskeleton designed to provide unique value in three areas of practice: neuroscience and movement science research, movement disorder assessment, and rehabilitation. About Curexo, Inc.Curexo Inc. is dedicated to developing cutting edge medical robots with the aim to provide value in life beyond treatment for a healthier tomorrow. CUREXO manufactures two surgical robots, CUVIS-joint and CUVIS-spine, along with one rehabilitation robot, Morning Walk S200. Listed in the Korean Stock market, CUREXO plans to increase its scale by growing internationally and working with global partners. Find out more at www.curexo.com/english/ source : https://www.prnewswire.com/news-releases/curexo-incs-robotic-gait-training-system-morning-walk-s200-installed-in-first-us-inpatient-rehabilitation-facility-301783789.html?tc=eml_cleartime

View More

Bionik Laboratories' InMotion® Robotic Devices on Display at the Korea International Medical & Hospital Equipment Show (KIMES)

Bionik Laboratories Corp. (OTCPINK: BNKL), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges, offering its technology to therapists directly and offering services to patients in its clinical centers, today announced its InMotion® Robots will be on display at the Korea International Medical & Hospital Equipment Show (KIMES) from March 23 ? March 26, 2023. Through the Company's exclusive distribution partner Curexo in South Korea, attendees looking for innovative medical technologies will be able to demo the devices live and learn more about their role in recovery following a stroke and other neurological conditions.Curexo, a recognized leader in medical device distribution and Bionik's distribution partner in South Korea, continues to penetrate the Asian market on behalf of Bionik. The Company received regulatory approval for the InMotion® robotics technology from the South Korean Ministry of Food and Drug Safety in early 2020. Curexo's recent sales and installations of the InMotion® devices in South Korea included Pusan National University's Yangsan Hospital (PNUYH), Seoul National University Hospital (SNUH), Myongji Choonhye Hospital, and various Veteran's hospitals.Bionik's fleet of InMotion® Robots for rehabilitation following a stroke help patients to regain arm and hand movement. Where conventional therapy alone can only allow patients to do 30-60 repetitive movements an hour, the InMotion® devices have patients completing 600 - 1,000 movements an hour. The robotic device assists patients as needed while it measures the position, speed and acceleration to adjust to the patient's needs during that session. In a recent whitepaper, Using Data Analytics to Quantify InMotion Robotic Systems' Impact on Neuroplasticity, improvement rates of patients utilizing InMotion® robotic devices measured upwards of 15-20% over a 14-day time-."We value our long-standing partnership with Curexo, and their commitment to bring advancements in stroke recovery care to the South Korea market," said Richard Russo Jr., CEO of Bionik Labs. "Our data-driven robotic therapy system has been featured in published research within dozens of medical journals, pointing to its effectiveness. We look forward to continuing to bring Bionik's proven therapeutic gains to Curexo's customers in the years ahead."Curexo will be showcasing Bionik's InMotion® devices at KIMES in their booth, located at 3F, Hall C, #C200. To learn more about KIMES 2023, please visit here: https://kimes.kr/eng/. To learn more about Bionik and its InMotion® devices, please visit here. https://bioniklabs.com/About Bionik Laboratories Corp.Bionik Laboratories is a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges. The Company offers its technology to therapists directly and offers services to patients in its clinical centers. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. For more information, please visit www.Bioniklabs.com and connect with us on Twitter, LinkedIn, and Facebook.Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "possible," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology.Forward-looking statements may include, without limitation, statements regarding (i) the plans and ives of management for future operations, including plans or ives relating to the design, development and commercialization of robotic rehabilitation products and the roll-out of its recently-announced Neuro-Recovery Centers of Excellence strategy, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, including as a result of the acquisition and rebranding of the Company's Neuro-Recovery Centers of Excellence, and the future financial performance of any such Centers of Excellence the Company may acquire or launch (iv) the market and projected market for our existing and planned products and services and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above.Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, ives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward- looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing or increase revenue, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development and sales of our products and related insufficient cash flows and resulting illiquidity, the continued impact on the Company's business as a result of the Covid-19 pandemic, the Company's inability to expand the Company's business, including its recently launched Neuro-Recovery Centers of Excellence strategy, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.source : https://www.businesswire.com/news/home/20230323005413/en/Bionik-Laboratories%E2%80%99-InMotion%C2%AE-Robotic-Devices-on-Display-at-the-Korea-International-Medical-Hospital-Equipment-Show-KIMES

View More

THINK Surgical and CUREXO Announce Entry Into Development and Distribution Agreement

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced its entry into a development and distribution agreement with Curexo, Inc., a medical robotics specialist company based in South Korea. THINK and Curexo have a strong working relationship based on historical development collaboration and Curexo distributes THINK's TSolution One™ platform in Korea and Vietnam.Under the development and distribution agreement, THINK and Curexo will work together to include certain existing THINK technology and certain newly developed technology in Curexo's CUVIS-Joint orthopedic surgical robot platform. THINK will have exclusive rights to distribute the CUVIS-Joint robotic platform, including the additional technology, in the United States and other countries, including the United Kingdom and certain countries in the European Union.  The CUVIS-Joint robotic platform is currently being used by surgeons in Korea and India with great success. To date over 4,000 procedures have been performed. Curexo will continue to commercialize the CUVIS-Joint robotic platform, including new technology developed with THINK, outside of the countries in THINK's distribution territory. Curexo will also continue to distribute THINK's TSolution One™ platform in Korea and Vietnam.The CUVIS-Joint robotic platform is not yet cleared for sale in the United States. THINK will be responsible for seeking 510(k) clearance from the Food and Drug Administration (FDA) in the United States with support from Curexo to allow such sales. The companies will work together to seek regulatory clearance in other countries for the CUVIS-Joint robotic platform including additional technology."We are excited to deepen our relationship with Curexo and look forward to bringing the CUVIS-Joint platform to the United States and other markets," said Stuart Simpson, president and chief executive officer of THINK Surgical. "CUVIS-Joint is the next generation of active robot for joint replacement featuring an open implant library. As an open system that works with implants from multiple manufacturers, CUVIS-Joint is an outstanding fit within THINK's portfolio of products and services. THINK's open systems, including the CUVIS-Joint, offer a compelling alternative to closed systems which are limited to one manufacture's implants.""We are more than pleased to enter into this agreement with THINK, a long-standing financial and business collaborator of Curexo," said JJ Lee, chief executive officer of Curexo. "THINK is well positioned to successfully launch the CUVIS-Joint platform in these key markets, and Curexo has great confidence in the new leadership of THINK, led by CEO Stuart Simpson, given Stuart's deep experience in the orthopedic surgical robot business. We look forward to cooperating with THINK to obtain FDA clearance, develop new technology, and deliver new experiences with this next generation of active robot, thereby proving the value of the CUVIS-Joint platform to hospitals and surgeons in these important markets."About THINK Surgical®, Inc.THINK Surgical, Inc., a privately held U.S.-based medical device and technology company, develops, manufactures, and markets active robotics for orthopedic surgery. The TSolution One® Total Knee Application includes the only commercially available, active robot for total knee arthroplasty (TKA) utilizing an open implant library, supporting a variety of implant options.  The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide.THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology.  Please refer to the instructions for use for the TSolution One Total Knee Application for a complete list of indications, contraindications, warnings, and precautions. For additional product information, please visit www.thinksurgical.com.THINK Surgical and TSolution One are registered trademarks of THINK Surgical, Inc. ?2022 THINK Surgical, Inc. All rights reserved.About Curexo, Inc.Curexo Inc. is dedicated to developing cutting edge medical robots with the aim to provide value in life beyond treatment for a healthier tomorrow. Curexo manufactures two surgical robots, CUVIS-joint and CUVIS-spine, along with one rehabilitation robot, Morning Walk S200. Listed in the Korean Stock market, Curexo plans to increase its scale by growing internationally and working with global partners.Source : https://www.prnewswire.com/news-releases/think-surgical-and-curexo-announce-entry-into-development-and-distribution-agreement-301597044.html

View More

The steady supply of CUREXO, a medical robot. Supply volume increased significantly in the first quarter compared to the previous year.

Completed supply of 12 units in 1Q... The export of seven out of the 12 indicates a considerable achievement!Morning Walk covered by Health Insurance, new government policy boosts the rehabilitation robot market.Curexo's quarterly robot sales (the number of units supplied is based on sales recognition).Curexo announced that it had supplied a total of 12 medical robots in the first quarter of 2022.The number of units supplied in the first quarter of this year increased particularly compared to the first quarter of 2020 and the first quarter of 2021. Furthermore, seven out of twelve units are of great significance for overseas export.According to Curexo, eight units of 'Cubis-Joint,' an artificial joint surgery robot, were supplied to domestic hospitals and seven units to India. And the gait rehabilitation robot 'Morning Walk S200' and the upper extremity rehabilitation robot 'In Motion' has been supplied with three units and one unit, respectively, to domestic rehabilitation hospitals.A Curexo official declared, "The main factors for expanding the supply of medical robots in the first quarter of this year are the additional orders for 'Cubis-Joint' from India, the application of health insurance for domestic rehabilitation robots, and the expectation of market expansion for the new government's rehabilitation robot policies." "Thanks to these factors, the number of cases of artificial joint surgery with the Cubism Joint continues to increase in domestic and Indian hospitals, and clinical surgery with the demo robot has also produced satisfactory results, leading to additional supply contracts," he added.Curexo CS team employees are installing the gait rehabilitation robot 'Morning Walk S200' at a rehabilitation hospital.Curexo CS team employees are installing the gait rehabilitation robot 'Morning Walk S200' at a rehabilitation hospital.Curexo CEO Jaejoon Lee said, "The medical robot business performance varies from quarter to quarter, but annual supply expansion and sales growth are noteworthy." "Despite the aggravated global supply chain and the coronavirus, we expect to record positive sales results in the first quarter because we are confident of securing inventory, shortening the production period, and delivering quickly," he counted. "In addition, we are promoting the excellence of Curexo medical robots by conducting continuous marketing through participation in medical device conferences held at home and abroad," he expressed.Meanwhile, Curexo's self-developed gait rehabilitation robot 'Morning Walk S200' started to be covered by health insurance from February 1 in accordance with a partial revision of the Ministry of Health and Welfare's 「Standards for Selection and Implementation of Selective Benefits」.A Curexo representative stated, "We are already close to our domestic sales target of 6 units. We had set for selling three units of the Morning Walk S200 in the first quarter and one unit in the second quarter." "We plan to raise our domestic sales target as we expect the sales increase with health insurance benefits, identified as the biggest obstacle, are resolved," he declared.source : http://www.k-health.com/news/articleView.html?idxno=58890

View More

New Strategic Partnership between CUREXO Inc. and Fourier Intelligence

Medical robot specialist CUREXO Inc. and rehabilitation robotics vanguard Fourier Intelligence announces their strategic global partnershipFrom top left : Mr Zen Koh, and Mr Jae Jun Lee. From bottom left: Mr Owen Teoh, Mr Jean Cho, and Ms Sandra Lee.Medical robot specialist CUREXO Inc. and rehabilitation robotics vanguard Fourier Intelligence announces their strategic global partnershipWe are excited for this strategic partnership with CUREXO to further enrich our global market offerings. Together, we will further our mission to providing intelligent rehabilitation technologies."Mr Zen Koh, CEO of Fourier Intelligence’s Global HubSINGAPORE, August 20, 2021 /EINPresswire.com/ -- Fourier Intelligence has announced a partnership with CUREXO Inc., the company behind the world’s first "fully automated surgical robot". This partnership will initially focus on the distribution of CUREXO’s Morning Walk to the global network.The Morning Walk from CUREXO is a gait rehabilitation robotics suited for pediatrics and adult populations. With the recent CE certification, it allows the novel end-effector gait rehabilitation robot to be offered into countries outside of Korea. This partnership leverages Fourier Intelligence’s vast network of global sales partners with its presence in over 50 countries such as Singapore, Malaysia, Thailand, the United Kingdom, Australia, and many more."We are excited for this strategic partnership with CUREXO to further enrich our global market offerings," said Zen Koh, Co-Founder and CEO of Fourier Intelligence’s Global Hub. "Together with Jae Jun and his team, we will also work towards future joint technological development, furthering our mission to providing intelligent rehabilitation technologies to empower clinicians and their patients."CUREXO’s CEO, Mr. Jae Jun Lee states that "I am thrilled for this partnership with Fourier Intelligence, which will be a great asset in getting awareness in the global market. The end-effector gait rehabilitation robot Morning Walk has 18 installation sites in Korea. Now is the time to move out to compete with the international ps, and this alliance with Fourier Intelligence’s Global Hub has given us the strength to start the journey."CUREXO is one of the many companies working together with rehabilitation robotics pioneer Fourier Intelligence in providing robotics for rehabilitation. The vanguard company works with various other well-known manufacturers to positively disrupt the industry and serves true to its mission as a ‘One-Stop Solution Provider of Robotics for All’. It recently completed an extended C+ round funding led by Prosperity7 Ventures, an Aramco Venture Fund, to further its global market expansion plan.The Morning Walk will now be part of Fourier Intelligence’s RehabHub™. The comprehensive rehabilitation concept is equipped with highly efficient, compact, modular, interconnected, and cost-effective robots that deliver efficacious functional training. Building upon group therapy models, the RehabHub™ serves well in rehabilitation to assist clinicians in providing highly intensive, challenging, and effective treatments. This constructively frees up the clinician from monotonous and tedious physical interventions to offer a personalized treatment program to patients.This partnership also brings together collective talents in technology development, deployment, product strategy roadmap, and innovation to support clients through lucrative healthcare transformations.About Fourier IntelligenceFourier Intelligence is a technology-driven company, infusing creativity into exoskeleton and rehabilitation robotics development since 2015. The company's name derives from 'Fourier Transform', which is named in honor of Jean-Baptiste Joseph Fourier (Mar 21, 1768 ? May 16, 1830), a French mathematician. Fourier Transform is a mathematical operation that changes the domain (x-axis) of a signal from time to frequency. Together with researchers, engineers, therapists, patients, and various strategic stakeholders, Fourier Intelligence aims to transform the industry by introducing an intuitive RehabHub™ and redefining rehabilitation and robotics solutions to enhance patients' lives.Find out more at www.fftai.comAbout CUREXO Inc.CUREXO Inc. is a dedicated medical health care robot development-orientated company that aims to provide value in life, not just treatment but beyond, to make a healthier tomorrow. CUREXO has a lineup of two surgical robots CUVIS-joint and CUVIS-spine, along with one rehabilitation robot, Morning Walk. Listed in the Korean Stock market, CUREXO plans to increase its scale by moving out internationally and working with global partners.Find out more at www.curexo.com/english/https://www.einnews.com/pr_news/549229897/new-strategic-partnership-between-curexo-inc-and-fourier-intelligence

View More

'Morning Walk S200', CUREXO's walking rehabilitation robot, has acquired European CE certification

SEOUL, South Korea, May 18, 2021 /PRNewswire/ -- On the 17th, the medical robot specialist company CUREXO (060280) announced that their next-gen walking rehabilitation robot, the 'Morning Walk S200', acquired CE certification. This is the 3rd certificate that the 'Morning Walk S200' has acquired, followed by MFDS (Korea) and FDA (US) certificates this February.The 'Morning Walk' of CUREXO is a walking rehabilitation robot for everyone from children to adults. Currently, it is being used by 16 rehabilitation hospitals in Korea to assist with patient rehabilitation.By acquiring the European CE certificate, the company can now advance to 28 EU countries, 3 EFTA countries, EU candidate countries and neutral countries. Also, after acquiring the MDFS (Korea), the company has recently won 2 national project contracts and has also been supplying its solution to the rehabilitation hospitals in the Gyeongbuk region.Many research papers prove the stability and usefulness of the 'Morning Walk' for cerebral stroke, spinal cord injuries, Parkinson's disease, peripheral nerve disease, and artificial knee joint patients.According to the article, 'Effects of robot-(Morning Walk ®) assisted gait training for patients after stroke: a randomized controlled trial' in the SCI Journal 'Clinical Rehabilitation, 2019, Vol.33' In a randomized control trial with 58 cerebral stroke patients to assess the rehabilitation performance of 'Morning Walk,' the 'Motricity Index' that indicates the strength of lower extremity and the 'Berg Balance Scale' that evaluates the patients' balancing ability have shown statistically significant improvements compared to the control group. 'Montricity Index' has improved approximately 69.8% and 'Berg Balance Scale' has improved approximately 49.0% compared to the control groups.According to the article 'Five-day rehabilitation of patients undergoing total knee arthroplasty using an end-effector gait robot as a neuromodulation blending tool for deafferentation, weight offloading and stereotyped movement: Interim analysis' published in the medical journal 'PLOS ONE, 2020 Vol.15', During 5 days of randomized control trials, the 'Morning Walk' and other medical walkers were used by artificial joint surgery patients. Based on the electrophysiological evaluation and biomechanical measuring technique, the patients who used 'Morning Walk' showed 2.65 times higher strength growth rate than the control group.According to the article, 'Feasibility of Robot-Assisted Gait Training with an End-Effector Type Device for Various Neurologic Disorders,' published in neurorehabilitation journal 'Brain & NeuroRehabilitation, 2020 Vol.13,' the control experiment with 100 brain injury patients, 40 spinal cord injury patients, 8 Parkinson's disease patients, 9 peripheral nerve disease patients, 22 pediatric patients (total 189) showed a significant improvement in both Medical Research Council (MRC) that evaluates the strength and Functional Ambulatory Category (FAC) that indicate walking ability.CEO Jae-Joon Lee stated "I am glad that the 'Morning Walk S200' has acquired European CE certification allowing us to expand our market to the European medical rehabilitation market, followed by Korea and the US." He also said that "Many research papers have confirmed that the rehabilitation utilizing 'Morning Walk' significantly improves stability and effectiveness compared to the control group. This demonstrates that the 'Morning Walk' has a wide range of applications. For the past years, we have listened to the feedback of our patients and medical staff who used 'Morning Walk' and continuously improved our solution. As a result, the 'Morning Walk' is now being supplied to 16 rehabilitation hospitals in Korea and is going to be sold overseas. As we have obtained the permits in the US and Europe, we plan to expand our business in the advanced medical market.Media ContactHoyong Lee, hylee@curexo.comSOURCE CUREXO

View More

CUREXO dashes into overseas markets with last year’s results, achieving best quarterly performance ever

Curexo, a medical robot company, said it recorded its highest quarterly performance thanks to increased sales of medical robots in the fourth quarter of 2020.According to the company, sales in the fourth quarter were 12.7 billion KRW (YoY +39%, QoQ +41.7%), operating profit was 14.8 billion (YoY surplus conversion, QoQ +250.1%), and net profit was 1.66 billion (YoY surplus conversion, QoQ +165%) respectively. The annual sales grew 14.2 percent year-on-year to 392.8 billion, operating profit reached 7.3 billion, and net profit reached 640 billion KRW, respectively.Curexo succeeded in expanding sales and making a surplus by supplying its medical robots to various internal and external medical sites last year.Specifically, last year's results included a total of 18 units, including eight artificial joint surgery robots, "CUVIS-joint," three spinal surgical robots, "CUVIS-spine," and five walking rehabilitation robots, "Morning Walk," to the domestic and overseas medical markets. As a result, Curexo has established itself as a leading medical robot company in Korea and has secured both growth and profitability.The company's CEO, Lee Jae-jun, said, "As a representative of the company, I am grateful that we were able to supply medical robots to the domestic and overseas medical markets with the dedication and efforts of executives and employees even amidst COVID-19.""In the second quarter of this year, we are aiming to obtain domestic and overseas licenses," he added. "We will not stop at last year’s success but do our best to advance into developed markets such as the U.S. and Europe, the cores of global medical robot markets, establishing the status of K-medical robots in the global medical robot market by signing strategic partnerships, promoting joint projects, and building brand awareness and expanding supplies."https://www.k-health.com/news/articleView.html?idxno=52292

View More

"CUVIS-spine," CUREXO's spinal surgical robot... success of its first surgery at the Severance Hospital

"CUVIS-spine," spinal surgical robot developed by CUREXO, the medical robot specialized company, successfully performed its first operation at the Severance Hospital, Sinchon.According to the company, "CUVIS-spine" had successfully carried out the insertion of pedicle screws on a patient with spinal stenosis and degenerative spondylolisthesis. After the surgery, image examinations had proven the fixation of the screws as originally planned, and the patient was able to leave the hospital on the fifth day with improvements.Dr. Seong Yi?of the department of neurosurgery at the Severance Hospital, Sinchon?is inserting the screws using CUVIS-spine.Until now, to increase the surgical accuracy, movable X-ray equipment, C-arm, was used and observed in real-time, which raised the risk of exposure to radiation for both the patients and medical team. But surgery with robots enables accurate and safe operation without such risk.CUVIS-spine, especially, is the first spinal surgical robot to be domestically developed in the country and fifth to be commercialized in global medical fields.CUVIS-spine is equipped with the system of a spinal surgical robot that guides the location and position of surgical instruments, and surgical accuracy increases as it plans a surgery based on 2D C-arm or 3D CT images and corrects while monitoring the patient's posture in real-time during the insertion of pedicle screws into patients with spinal stenosis, spinal disc herniation, or scoliosis. Also, safety increases as the exposure to radiation are lessened during the surgery. Thanks to this, patients can quickly return to their daily lives."I expect that Korean robots will be able to enter the market by accumulating track records and creating clinical evidence in the field of spinal surgical robots, which is expanding globally," Dr. Seong Yi, of the department of neurosurgery at Severance Hospital, who participated in developing CUVIS-spine, said. "Linked with the Medical Robot Training Center?which will be established at the Severance Hospital over the next five years?the clinical data of spinal surgical robots, including safety, validity, and radiation safety level will contribute to the development and globalization of the domestic surgical robot industry."Severance Hospital said it would apply CUVIS-spine to a total of 50 spinal surgeries this year, followed by the introduction of the robot."This successful spinal robotic surgery at the Severance Hospital is a great chance to prove the excellence of our medical robot," CEO Jae-jun Lee of CUREXO commented. "In the future, we will develop more advanced medical robots and actively proceed with the entry of domestic and overseas medical sites through our continued cooperation with the Severance Hospital."Meanwhile, CUVIS-spine had acquired CE markings from the Ministry of Food and Drug Safety last December and from Europe last May. It completed submitting s to the U.S. FDA and is now waiting for approval.http://www.k-health.com/news/articleView.html?idxno=51098